Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study

Journal of Thrombosis and Thrombolysis

Volumn 15, Issue 1, 2003, Pages 41-46

  Go, Allan S ^a,b   Reed, Guy L ^c   Hylek, Elaine M ^d   Phillips, Kathleen A ^a   Liu, Lin ^c   Henault, Lori E ^d   Selby, Joe V ^a   Singer, Daniel E ^d  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anticoagulants; Atrial fibrillation; Genetics; Stroke

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; GENETIC POLYMORPHISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOEMBOLISM; VEIN THROMBOSIS;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; EPIDEMIOLOGY, MOLECULAR; FACTOR V; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS;

EID: 0242721275     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026192301848     Document Type: Article

References (20)

1. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
2. Go AS, Hylek EM, Phillips KA, et al. Implications of stroke risk criteria on the anticoagulation decision in non-valvular atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation 2000;102:11-13.
3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870.
4. Pearce LA, Hart RG, Halperin JL. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med 2000;109:45-51.
5. Thomson R, McElroy H, Sudlow M. Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: Variation in content and implications for treatment. BMJ 1998;316:509-513.
6. Grossman W, Barry W. Cardiac catheterization. In: Braunwald E., ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: Saunders, 1988:242-267.
7. Hart RG, Pearce LA, Miller VT, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: Frequency and effect of antithrombotic agents in the Stroke Prevention in Atrial Fibrillation studies. Cerebrovasc Dis 2000;10:39-43.
8. Lee R. Factor V Leiden: A clinical review. Am J Med Sci 2001;322:88-102.
9. Middeldorp S, Meinardi JR, Koopman MM, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001;135:322-327.
10. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-917.
11. Feinberg WM, Pearce LA, Hart RG, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: Correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999;30:2547-2553.
12. Eikelboom J, Thom J, Van Bockxmeer F, Baker R. Does activated protein C resistance increase the risk of systematic embolism in non rheumatic atrial fibrillation? Aust N Z J Med 1996;26:243-244.
13. Pengo V, Filippi B, Biasiolo A, Pegoraro C, Noventa F, Iliceto S. Association of the G20210A mutation in the factor II gene with systemic embolism in nonvalvular atrial fibrillation. Am J Cardiol 2002;90:545.
14. Hankey GJ, Eikelboom JW, Van Bockxmeer FM, Lofthouse E, Staples N, Baker RI. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001;32:1793-1799.
15. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999;131:927-934.
16. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
17. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001;285:2370-2375.
18. Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 1997;20:1396-1402.
19. Wacholder S. Practical considerations in choosing between the case-cohort and nested case-control designs. Epidemiology 1991;2:155-158.
20. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 2002;288:2441-2448.